In the latest episode of the BBC’s show, “Trust me, I’m a Doctor”, an innovative new product called Magseed is being trialled to improve surgery for women with breast cancer. A tiny magnetic seed is being used to transform how cancerous tissue is localised so that it can be removed, rather than using traditional guide wires. This helps the surgeons pinpoint exactly where they need to operate, and which angle is the best to approach the tumour. Much smaller tumours are currently being detected through the breast cancer screening programme, which are more difficult to find during surgery using guide wires.
Aquarius Population Health is excited to participate in the 2018 MedTech Forum in Brussels on the 23-25th January. The MedTech Forum is one of the largest health and medical technology industry conferences in Europe. Since 2007, it provides participants with the chance to gather insights on the latest industry trends, as well as networking opportunities with other business leaders, leading innovators and investors. The MTF 2018 programme will focus on digital developments, new business strategies and innovation.
We’re pleased to welcome a new member of the Aquarius team. Beth Shead joined the team in October as our new Research Assistant. She will primarily support our work on patient pathways and micro-costing in sexual health clinics as part of a larger Innovate UK funded project with Atlas Genetics and St. George’s University of London. Beth will also support some of the diverse projects which Aquarius are currently working on.
Aquarius Population Health, a leading independent health economics consultancy, worked with Chelsea and Westminster NHS Foundation Trust to assess the impact of Dean Street Express, their award winning sexual health clinic in Soho, London. This service tests symptom-free people wanting a routine sexual health check-up using an on-site 90-minute chlamydia and gonorrhoea rapid test. They estimated the patient and public health benefits of their rapid testing service, and compared to the standard sexual health service that didn’t offer rapid delivery of test results.
What do digital health, health economics, making better decisions, and zombies have in common? Much more than you think!
We recently attended the the Digital Art of the Possible 2 (DAP2) event hosted by the West of England Academic Health Science Network (WEAHSN) with our good friend, Charles Lowe, from the Digital Health and Care Alliance . At the DAP2 event, the future of digital health technology in the NHS was discussed including case studies of what has worked well across the area. Elisabeth said a few words about the importance of digital health technology to businesses and the NHS (video).
Work has begun to develop a digital value proposition tool for a novel rapid sexually transmitted infection (STI) test
London, UK, 14 August 2017
Aquarius Population Health, a leading independent health economics consultancy, has recently been awarded an 18-month Innovate UK grant in collaboration with Atlas Genetics Ltd and the Applied Diagnostic Research and Evaluation Unit at St George’s University of London (total £2,000,000). The funding will be used to develop evidence for health services to support the introduction of a new rapid diagnostic test. In 30-minutes the test can diagnose multiple sexually transmitted infections including chlamydia and gonorrhoea – infections which could take up to a week to diagnose using the current laboratory testing systems.
Aquarius Population Health recently worked with the Applied Diagnostic Research & Evaluation Unit (ADREU) at St. Georges, University of London, to assess the cost-effectiveness of six hypothetical strategies for using antimicrobial resistance point-of-care testing to guide the treatment of gonorrhoea. Our findings were presented at the STI & HIV World Congress in Rio de Janeiro, Brazil. [Wednesday 12th July, Session 15: STI/HIV testing and management].
We were a collaborator on a recent Innovate UK-funded SBRI project with Atlas Genetics and the Applied Diagnostic Research and Evaluation Unit at St George’s University of London. In this project, our team compared the overall costs, patient benefits and cost-effectiveness of three different multi-pathogen point-of-care testing strategies with the current strategy of microscopy and lab-based testing.
Personalised medicine is an emerging field that brings exciting changes to patient care. So, what exactly is personalised medicine and what are its benefits?
In the past, various terms have been used interchangeably: ‘stratified medicine’, ‘personalised medicine’ and ‘precision medicine’. These terms refer to data driven medicine, in which data can be a patient’s genetic makeup, molecular data or disposition to respond to therapy. These data allow for a targeted approach to prevention, diagnosis and treatment using technologies such as genomic medicine, diagnostic tests, predictive data analytics or real-time patient monitoring.
In a study commissioned by the Review on Antimicrobial Resistance, Aquarius Population Health worked with modellers at the University of Bristol to create a mathematical model. The model was used to assess the economic implications and treatment impact of introducing a hypothetical antimicrobial resistance (AMR) point-of-care test (POCT) for gonorrhoea. Results of the study were published this week in BMJ Open.